Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 11
2020 10
2021 10
2022 9
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution.
Gutkind JS, Faraji F, Ramirez S, Clubb L, Sato K, Quiroz PA, Galloway W, Mikulski Z, Hoang T, Medetgul-Ernar K, Marangoni P, Jones K, Officer A, Molinolo A, Kim K, Sakaguchi K, Califano J, Smith Q, Klein O, Tamayo P. Gutkind JS, et al. Res Sq [Preprint]. 2023 Oct 27:rs.3.rs-3426301. doi: 10.21203/rs.3.rs-3426301/v1. Res Sq. 2023. PMID: 37961717 Free PMC article. Preprint.
Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors.
Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS, Ramamoorthy Premlal AL, Griswold RQ, Dolina JS, Cohen EEW, Miller AM, Peters B, Schoenberger SP. Brightman SE, et al. Nat Immunol. 2023 Aug;24(8):1345-1357. doi: 10.1038/s41590-023-01543-9. Epub 2023 Jul 3. Nat Immunol. 2023. PMID: 37400675 Free PMC article.
The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.
Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS. Wu VH, et al. Nat Immunol. 2023 Aug;24(8):1318-1330. doi: 10.1038/s41590-023-01529-7. Epub 2023 Jun 12. Nat Immunol. 2023. PMID: 37308665 Free PMC article.
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.
Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, Goudarzi S, Kirani D, Au J, Zhang T, Landi T, Salem RM, Morris GP, Harismendy O, Patel SP, Alexandrov LB, Mesirov JP, Zanetti M, Day CP, Fan CC, Thompson WK, Merlino G, Gutkind JS, Vijayanand P, Carter H. Pagadala M, et al. Nat Commun. 2023 May 12;14(1):2744. doi: 10.1038/s41467-023-38271-5. Nat Commun. 2023. PMID: 37173324 Free PMC article.
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer.
Saddawi-Konefka R, Schokrpur S, Lui AJ, Gutkind JS. Saddawi-Konefka R, et al. Cancer J. 2022 Sep-Oct 01;28(5):339-345. doi: 10.1097/PPO.0000000000000622. Cancer J. 2022. PMID: 36165721 Free PMC article. Review.
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.
Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang NA, Msari RA, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS. Saddawi-Konefka R, et al. Nat Commun. 2022 Jul 25;13(1):4298. doi: 10.1038/s41467-022-31941-w. Nat Commun. 2022. PMID: 35879302 Free PMC article.
44 results